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Sequences of the HIV-2 envelope C2–C3 region were obtained after direct PCR amplification of proviral DNA from the
brain and peripheral blood mononuclear cells of an HIV-2-infected AIDS patient. Tissue-specific sequences confirmed
previous observations that HIV-2 is indeed present in the central nervous system of infected individuals. Distinct but related
quasi-species were present in these two different tissues of the same individual. Residues at position 18 and 19 of the V3
loop and overall charge of the loop suggest that the brain virus was NSI/macrophage tropic; whereas the sequences from
the two blood samples were indicative of a SI/T-cell tropic virus. This is the first description of these two genotypes in the
same HIV-2-infected individual. Analysis of more samples from different compartments would help to better understand
tissue-specific factors in quasi-species evolution in vivo. q 1996 Academic Press, Inc.
HIV-2, the second human lentivirus, was first recognized may also be dependent on utilization of different corecep-
tors, fusin in the case of T-cell lines, and CC-CKR5 forin West Africa where it is endemic (6, 12, 17). It is associated
with AIDS in infected individuals but differs from HIV-1 in macrophages (13, 14, 19). The V3 loop may be the deter-
minant for usage of such coreceptors in HIV-1 (11). Inits epidemiology and relative pathogenicity: HIV-2 is less
transmissible and much less pathogenic than HIV-1 (4, 17, the case of HIV-2, determinants of tropism are not yet
fully characterized, but the V3 loop has been implicated27, 36). HIV-1 has been described in the central nervous
system of a significant number of infected individuals and in viral fusion (21). Recently, tropism and replication ki-
netics of HIV-2 has been shown to correlate with the V3is associated with encephalitis and dementia. There is less
information on HIV-2 involvement in the central nervous genotype (2). The HIV-2 V3 loop is also known to contain
an immunodominant domain and a neutralizing epitopesystem to date. HIV-2 has been detected in the central
nervous system tissue of two infected patients with neuro- (8, 24, 37, 38). Furthermore, in the closely related simian
immunodeficiency viruses (SIV), there is evidence thatlogical symptoms (15). Several clinical case reports associ-
ate HIV-2 with neurological manifestations (7, 23, 25, 30, the V3 loop is a determinant of cell tropism (23). Thus,
this region of the envelope is likely to demonstrate tissue-35, 43).
Primate lentiviruses are thought to infect microglial specific variation during natural infection depending on
the type of infected cells in different tissue compartmentscells in the central nervous system (51). These cells are
readily infected by strains of HIV-1 that are nonsyncytium and its local immune milieu.
We report here sequences of the envelope V3 loopinducing/macrophage tropic (NSI) but not by syncytium
inducing/T-cell tropic (SI) viruses (51). A study of in vitro and flanking regions obtained after direct PCR amplifica-
tion of proviral DNA from the brain and the peripheralinfection of microglial cells from primary human brain
cultures suggested that HIV-2 strains may be less infec- blood of an HIV-2-infected AIDS patient. Distinct but re-
lated quasi-species were present in these two compart-tious to these cells than HIV-1 strains (51). No HIV-2
viruses isolated from the brain have been previously de- ments of the same individual, suggesting parallel evolu-
tion and differential tropism.scribed or genetically analyzed. In HIV-1, determinants
of differential tropism for macrophages or lymphocytes The patient was a 39-year-old Cape Verdean male HIV-
2-infected AIDS patient in Boston, receiving 3*-azido-3*-have been mapped to the V3 loop of the envelope surface
protein (26). It has recently been shown that this tropism deoxythymidine (AZT) therapy at the time of the first blood
sample and who died 1 year later. The patient’s present-
ing symptoms were previously described (5). He subse-1 To whom correspondence and reprint requests should be ad-
dressed. quently developed Pneumocystis carinii pneumonia and
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toxoplasma encephalitis shortly before his death. Brain present in the V3 loop was conserved in all samples.
and peripheral blood samples were collected immedi- One of two glycosylation sites in the C3 was conserved
ately postmortem (45). between the blood samples but absent in all sequences
DNA was extracted from frozen tissues by Proteinase from the brain sample (NFT r NFA).
K-phenol extraction. A heminested polymerase chain re- We obtained partial sequences (V3 loop) on additional
action (PCR) was performed to amplify a 524-bp fragment clones, 11 clones for the first blood sample, 9 clones for
containing the C2–V3–C3 region. Sequences of the the second blood sample, and 9 clones for the brain
primers and the PCR reactions conditions have been sample were included in the analysis of the V3 loop.
previously described (45). The PCR product was purified Again, no viral brain sequences were similar to any viral
by agarose gel electrophoresis and cloned in the pCRII blood sequence. On this larger number of clones we
vector (T/A cloning, Invitrogen, San Diego, CA). Plasmid examined the 6 residues that distinguished the viral brain
preparation for double-stranded DNA sequencing was sequences from the blood sequences. The 1 amino acid
performed by alkaline lysis. Complete C2–V3–C3 se- insertion/deletion was consistently present as well as 4
quences were determined by chain-termination method of the substituted residues. The additional substitution
using T7 polymerase (Sequenase 2, United-States Bio- was present in all except 1 of the 9 brain clones, but
chemicals Corp., Cleveland, OH). Partial sequences (V3 also present in 2 of 9 clones of the synchronous blood
loop, cysteine to cysteine) were obtained on additional sample.
clones. We analyzed the number of positively charged resi-
Analysis, alignment, and comparison of the sequences dues in the V3 loop sequences. In 18 of 20 clones from
obtained were performed with the GeneWorks software both blood samples, the V3 loop had 8 charged residues.
(IntelliGenetics, Mountain View, CA) and the Clustal The remaining two clones had 7 charged amino acids.
package of multiple alignment programs (Clustal W 1.6) Of 9 viral sequences from the brain, 6 clones had 5
with minor manual adjustment. Phylogenetic analysis charged residues and 3 clones had 6 charged residues
was performed using the Clustal package (Clustal W 1.6) (Table 1). The average net charge was 8 for the first
and the Phylip (version 3.5) package (18, 49). The nucleo- blood sample sequences, 7.8 for the second blood sam-
tide sequences have been submitted to GenBank (Acces- ple sequences, and 5.3 for the brain sample sequences.
sion Nos. U24369–U24388 and U71302–U71319).
To evaluate the relatedness of the two sets of se-
We sequenced the C2–V3–C3 region (464 to 467 bp)
quences and their relationship to other HIV-2 sequences,
of five clones from the first PBMC sample, four from the
we performed a phylogenetic analysis of the C2–V3– C3
second PBMC sample, and four from the brain sample.
sequences. We performed a neighbor-joining tree withWe examined the deduced amino acid sequence from
100 bootstrap replica (Fig. 2). The tree shows that thethese clones (Fig. 1). The sequences from the PBMC
sequences from our patient are indeed related, formingtaken 1 year apart were very similar to each other (2.2%
a cluster apart from sequences from the literature andaverage amino acid difference). Only two conservative
sequences obtained from other HIV-2-infected individu-substitutions among the 155 amino acids were consis-
als (40, 45), confirming their common origin (32, 33).tently present between the two samples. A proline was
Within that cluster the sequences from the two compart-substituted for a serine in the C2 region and an arginine
ments segregated according to their tissue of origin.for a lysine in C3. In contrast when the sequences from
These clusters were supported by high bootstrap values.the brain were compared to the sequences from the
The tree also indicated that the HIV-2 virus infecting thisblood compartment twelve positions distinguished the
individual is subtype A (22).brain from the blood sequences. Half of these changes
This report extends our observations that little geneticwere located in the V3 (one insertion/deletion and five
variation was observed over time in the peripheral bloodsubstitutions) and the other half in the C3 (six substitu-
compartment of HIV-2-infected individuals (45). In thistions). Three of the substitutions in the V3 loop involved
study, we show that in one of these patients the envelopecharged amino acids that were replaced in most clones
sequences remained highly conserved in the C2 and C3by noncharged amino acids. At the nucleotide level, a
regions, as well as in the V3 loop, as previously reported.few synonymous substitutions also distinguished the se-
In sharp contrast, a distinct but related quasi-speciesquences from the two compartments, three in the C2
was concomitantly evolving in the brain of the same indi-region, one in the V3 loop, and one in the C3 region (data
vidual. As described in other lentiviruses infections, se-not shown).
quences derived from different organs segregate to-We also examined potential N-linked glycosylation
gether and are often distinct from one organ to the othersites in the sequenced envelope fragment (Fig. 1). Among
(1, 10, 28, 31, 41, 48). A parallel evolution of viral quasi-10 N-linked glycosylation sites, 7 were located in C2; 6
species may occur in different organs. The envelope sur-were conserved, and 1 was present in the first blood
face protein contains determinants of tropism and thesample and the brain sample but absent in the second
blood sample (NYS r NYP). The only glycosylation site differences observed are likely to reflect a selective tis-
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FIG. 1. Amino acid alignment of the sequences from the blood and the brain. The V3 loop is underlined. The potential N-linked glycosylation
sites are indicated by asterisks. Nonconserved glycosylation sites are underlined. ‘‘-’’ indicates that the amino acid is identical to consensus. ‘‘.’’
indicates a deletion relative to the consensus.
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TABLE 1 sponding to the SI/T-cell tropic phenotype has been primar-
ily obtained from T-cell line-adapted isolates, with the ex-Comparison of Charged Residues in the V3 Loop
ception of two sequences from uncultured PBMC (9, 45).
No. of clones with This represents the first instance where two genotypes
5 6 7 8 of HIV-2 have been found in the same individual, adding
Average significance to the correlation described in vitro (2). It is
charged residues chargea
possible that the difference observed between the two ge-
notypes might reflect a differential requirement for corecep-Blood sample 1 0 0 0 11 8
Blood sample 2 0 0 2 7 7.8 tor as has been described for HIV-1.
Brain sample 6 3 0 0 5.3 Epstein et al. proposed that because of the stable and
numerically limited character of the resident microgliala The average charge is a mean of the number of charged residues
cells in the brain, they were more likely to contain virusin all the sequences from one sample. This corresponds to the net
strains representing virus from early infection (16). Al-charge; there were no negatively charged residues. The difference
observed between blood and brain samples was statistically significant though such a hypothesis is difficult to test, the pheno-
(Student’s t test, P  0.001). typic characteristics of HIV-1 strains isolated from the
brain of infected individuals suggest that this may be the
case. The glycosylation pattern indicates that this may
sue-specific tropism and replication of the quasi-species also be true in our patient. An N-linked glycosylation site
in the brain. in the C2 region that was lost between the first peripheral
The presence of clones that are similar but distinct blood sample and the second was conserved in the brain
within the same site suggests the amplification of several sample that was collected at the time of that second
target molecules in the DNA sample. We cannot exclude, sample. This is further corroborated by the observation
however, that amplification of the same target may have that the V3 loop sequences found in the blood samples
occured and that the extent of quasi-species diversity are similar to sequences of viruses presenting a rapid/
might be under-represented (3, 34). high phenotype and isolated from a significant proportion
A number of characteristics in these HIV-2 sequences of HIV-2-infected patients with AIDS, whereas the se-
appear to parallel observations made in the HIV-1 sys- quences from the brain are closer to the consensus of
tem. Half of the amino acid substitutions observed in the HIV-2 V3 loop representative of sequences found in
464-bp fragment were located in the 102 bp of the V3 asymptomatic subjects (2, 9, 39, 40, 45, and unpublished
loop. Three substitutions resulted in a change of the observations). In this study, the effect of short term AZT
net charge of the V3 loop. In HIV-1-infected individuals, therapy may have also played a role in differential repli-
viruses found in the brain tissue are generally of the cation of viruses in blood and brain and their subsequent
NSI/macrophage-tropic phenotype (31, 41, 42). This is evolution of quasi-species.
believed to be due to the nature of the cells infected in The envelope V3 loop and possibly the C3 region are
the central nervous system. Microglial cells, the primary submitted to immune selection pressure in HIV-1-in-
targets of HIV-1 infection in the brain, are myeloid-de- fected individuals (44, 50). In HIV-2, the V3 loop is also a
rived macrophage-like resident cells. Determinants of site of potential immune pressure (8, 37, 38). The central
tropism in HIV-1 and SIV have been mapped to the V3 nervous system is immune sheltered and immune pres-
loop of the envelope surface glycoprotein (26, 29, 46, 47). sure is probably not a determinant factor in viral evolu-
In HIV-1 a lower net charge of the V3 loop has been tion. In the blood, however, strong immune pressure may
associated with the NSI/macrophage tropic phenotype be present and the variation from the brain sequences
(20). The determinants of cell tropism for HIV-2 have not could result in part from immune selection. This contribu-
yet been mapped. However, a correlation between the tion of the immune selection process is not exclusive of
number of charged residues in the V3 loop, the nature the tropism and fitness selection mechanisms that may
of the residues at positions 18 and 19 of the V3 loop, occur in the two different tissue compartments.
and the phenotype of HIV-2 isolates have been described In this study we have shown that distinct but related
(2). The sequences obtained from the brain of this individ- quasi-species can be present in different tissue compart-
ual had 3 to 4 less charged residues than the sequences ments of HIV-2-infected individuals. Tissue-specific se-
from the blood (Table 1). In addition, a leucine residue quences confirm previous observations that HIV-2 is in-
was observed in position 18 and a valine in position 19, deed present in the central nervous system of infected
in all clones from the brain (Fig. 1). These amino acid individuals. The mechanism responsible for parallel evo-
changes are characteristic of most slow/low, macro- lution of the virus in different organs remains to be eluci-
phage-tropic isolates of HIV-2 (2). This therefore sug- dated, but tissue-specific tropism, replication, and host
gests that the virus present in the brain might be of an NSI/ immune response need to be considered. These findings
macrophage-tropic phenotype and the one in the blood of indicate the need for more studies to characterize the
HIV-2 envelope and its relationship to pathogenesis, cellan SI/T-cell tropic phenotype. Thus far the genotype corre-
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FIG. 2. Phylogenetic tree of the V3 region of HIV-2. The neighbor-joining tree was performed using the Kimura’s two-parameter method and by
removing positions at which gaps were created. Numbers indicate bootstrap values (100 bootstrap samples). Taxa in italics are published sequences
retrieved from Los Alamos HIV Database (40). Additional sequences obtained from other patients (45) were included for comparison (taxa in bold).
Blood 1 and Blood 2 refer to first and second blood samples, respectively. Brain refers to the brain sample. The letters A and B refer to the two
major subtypes of HIV-2 described (22). The scale bar represents 10% nucleotide sequence divergence.
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